Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01110421 · ClinicalTrials.gov registry record · Phase 3
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
A Phase 3 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT01110421 is a Phase 3 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 7 participants.
The verdict
NCT01110421, a Phase 3 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with pneumonia.
Interventions
- DRUG Cefepime
- DRUG Doripenem
- DRUG Cefepime placebo
- DRUG Doripenem placebo
- DRUG Amoxicillin/clavulanate potassium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01110421
The ClinicalTrials.gov registry entry for NCT01110421 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cefepime is the first listed.
NCT01110421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01110421 about?
NCT01110421 is a clinical study titled "A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia". The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with pneumonia.
What is the current status of trial NCT01110421?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2010-12. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01110421?
The interventions under investigation include: Cefepime (DRUG), Doripenem (DRUG), Cefepime placebo (DRUG), Doripenem placebo (DRUG), Amoxicillin/clavulanate potassium (DRUG).
Who is sponsoring clinical trial NCT01110421?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.